Research programme: antibacterials - RecombinoGenAlternative Names: Rumycin 1; Rumycin 2
Latest Information Update: 18 Jan 2011
At a glance
- Originator RecombinoGen
- Class Cyclic peptides; Lipoproteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 04 Dec 2007 This research programme is available for licensing worldwide (http://www.recombinogen.com)